EczemaNCT07700745
A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin
A study testing Rejuvaskin Eczema Body Wash in people with Eczema and Atopic Dermatitis, run by Rejuvaskin at 1 site in United States.
Trial summary
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Eczema, Atopic Dermatitis, Eczema-Prone Skin
- What is being tested?
- Rejuvaskin Eczema Body Wash
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Jul 2026to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult women or men aged 18-65 years.
- Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
- Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
- Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
- Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
- Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration.
Show all 10Show fewer
- Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone.
- Able to read, understand, and complete questionnaires in English.
- Resides in the United States with a valid shipping address.
- Willing to provide informed consent and comply with all study procedures
Who cannot join
- Known allergy or sensitivity to any ingredient in the study product.
- Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
- Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
- Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
- Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.
- Conditions
- Eczema, Atopic Dermatitis, Eczema-Prone Skin
- Being tested
- Rejuvaskin Eczema Body Wash
- Medical subject headings
- Eczema, Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rejuvaskin Eczema Body WashDietary supplement
Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.
| Study group | Role | What they receive |
|---|---|---|
| Rejuvaskin Eczema Body Wash Arm | Experimental | Not described Receives: Dietary Supplement: Rejuvaskin Eczema Body Wash |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Self-Reported Skin Dryness
Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform
Measured: Baseline to Week 4
Change from Baseline in Self-Reported Skin Roughness
Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform
Measured: Baseline to Week 4
Change from Baseline in Self-Reported Skin Itch
Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform
Measured: Baseline to Week 4
Change from Baseline in Self-Reported Skin Irritation
Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform
Measured: Baseline to Week 4
Change from Baseline in Self-Reported Skin Discomfort
Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform
Measured: Baseline to Week 4
Secondary outcomes (4)
Change from Baseline in Self-Reported Skin Hydration
Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire
Measured: Baseline to Week 4
Change from Baseline in Self-Reported Skin Comfort
Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire
Measured: Baseline to Week 4
Expert Dermatologist-Graded Change in Erythema
Independent expert dermatologist grading of change in erythema from standardized photographs of a designated affected body area
Measured: Baseline and Week 4
Expert Dermatologist-Graded Change in Scaling
Independent expert dermatologist grading of change in scaling from standardized photographs of a designated affected body area
Measured: Baseline and Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start6 Jul 2026
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EczemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rejuvaskin
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07700745
- Sponsor's protocol ID
- REJUV-40748
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin
- ClinicalTrials.gov ID
- NCT07700745
- Acronym / sponsor ID
- REJUV-40748
- Conditions
- Eczema, Atopic Dermatitis, Eczema-Prone Skin
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- RejuvaskinIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 6 Jul 2026 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Rejuvaskin Eczema Body Wash Arm | Experimental | Dietary Supplement: Rejuvaskin Eczema Body Wash |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Adult women or men aged 18-65 years.
- Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
- Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
- Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
- Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
Key exclusion criteria (5 listed)
- Known allergy or sensitivity to any ingredient in the study product.
- Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
- Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
- Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
- Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rejuvaskin Eczema Body WashParticipants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks. | Dietary supplement | Rejuvaskin Eczema Body Wash Arm |
Primary outcome
Change from Baseline in Self-Reported Skin Dryness
Time frame: Baseline to Week 4
Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform
Change from Baseline in Self-Reported Skin Roughness
Time frame: Baseline to Week 4
Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform
Change from Baseline in Self-Reported Skin Itch
Time frame: Baseline to Week 4
Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform
Change from Baseline in Self-Reported Skin Irritation
Time frame: Baseline to Week 4
Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform
Change from Baseline in Self-Reported Skin Discomfort
Time frame: Baseline to Week 4
Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform
4 secondary outcomes
Change from Baseline in Self-Reported Skin Hydration
Time frame: Baseline to Week 4
Change from Baseline in Self-Reported Skin Comfort
Time frame: Baseline to Week 4
Expert Dermatologist-Graded Change in Erythema
Time frame: Baseline and Week 4
Expert Dermatologist-Graded Change in Scaling
Time frame: Baseline and Week 4
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Eczema
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rejuvaskin Eczema Body Wash in people with Eczema and Atopic Dermatitis, run by Rejuvaskin at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Self-Reported Skin Dryness (time frame: Baseline to Week 4). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.